NMDA receptor-mediated CaMKII/ERK activation contributes to renal fibrosis

BMC Nephrol. 2020 Sep 9;21(1):392. doi: 10.1186/s12882-020-02050-x.

Abstract

Background: This study aimed to understand the mechanistic role of N-methyl-D-aspartate receptor (NMDAR) in acute fibrogenesis using models of in vivo ureter obstruction and in vitro TGF-β administration.

Methods: Acute renal fibrosis (RF) was induced in mice by unilateral ureteral obstruction (UUO). Histological changes were observed using Masson's trichrome staining. The expression levels of NR1, which is the functional subunit of NMDAR, and fibrotic and epithelial-to-mesenchymal transition markers were measured by immunohistochemical and Western blot analysis. HK-2 cells were incubated with TGF-β, and NMDAR antagonist MK-801 and Ca2+/calmodulin-dependent protein kinase II (CaMKII) antagonist KN-93 were administered for pathway determination. Chronic RF was introduced by sublethal ischemia-reperfusion injury in mice, and NMDAR inhibitor dextromethorphan hydrobromide (DXM) was administered orally.

Results: The expression of NR1 was upregulated in obstructed kidneys, while NR1 knockdown significantly reduced both interstitial volume expansion and the changes in the expression of α-smooth muscle actin, S100A4, fibronectin, COL1A1, Snail, and E-cadherin in acute RF. TGF-β1 treatment increased the elongation phenotype of HK-2 cells and the expression of membrane-located NR1 and phosphorylated CaMKII and extracellular signal-regulated kinase (ERK). MK801 and KN93 reduced CaMKII and ERK phosphorylation levels, while MK801, but not KN93, reduced the membrane NR1 signal. The levels of phosphorylated CaMKII and ERK also increased in kidneys with obstruction but were decreased by NR1 knockdown. The 4-week administration of DXM preserved renal cortex volume in kidneys with moderate ischemic-reperfusion injury.

Conclusions: NMDAR participates in both acute and chronic renal fibrogenesis potentially via CaMKII-induced ERK activation.

Keywords: CaMKII; ERK; NMDA receptor; Renal fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzylamines / pharmacology
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / antagonists & inhibitors
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2 / metabolism*
  • Dextromethorphan / pharmacology
  • Dizocilpine Maleate / pharmacology
  • Epithelial-Mesenchymal Transition / drug effects
  • Epithelial-Mesenchymal Transition / physiology*
  • Excitatory Amino Acid Antagonists / pharmacology
  • Fibrosis
  • Gene Knockdown Techniques
  • Humans
  • In Vitro Techniques
  • Kidney / drug effects
  • Kidney / metabolism*
  • Kidney / pathology*
  • Kidney Tubules, Proximal / cytology
  • Mice
  • Mitogen-Activated Protein Kinase 1 / drug effects
  • Mitogen-Activated Protein Kinase 1 / metabolism
  • Mitogen-Activated Protein Kinase 3 / drug effects
  • Mitogen-Activated Protein Kinase 3 / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Receptors, N-Methyl-D-Aspartate / genetics*
  • Receptors, N-Methyl-D-Aspartate / metabolism
  • Renal Insufficiency, Chronic / metabolism*
  • Renal Insufficiency, Chronic / pathology
  • Reperfusion Injury / metabolism*
  • Reperfusion Injury / pathology
  • Sulfonamides / pharmacology
  • Transforming Growth Factor beta / pharmacology
  • Ureteral Obstruction / metabolism*
  • Ureteral Obstruction / pathology

Substances

  • Benzylamines
  • Excitatory Amino Acid Antagonists
  • NR1 NMDA receptor
  • Protein Kinase Inhibitors
  • Receptors, N-Methyl-D-Aspartate
  • Sulfonamides
  • Transforming Growth Factor beta
  • KN 93
  • Dizocilpine Maleate
  • Dextromethorphan
  • Calcium-Calmodulin-Dependent Protein Kinase Type 2
  • Mitogen-Activated Protein Kinase 1
  • Mitogen-Activated Protein Kinase 3